Millipore — Merger or Acquisition (March 2010)
11 slides from Millipore's merger presentation, Mar 1, 2010
Slide 1: All Employee Teleconference March 1st, 2010
All Employee Teleconference March 1 st , 2010
Slide 2: Forward Looking & Cautionary Statements
Forward Looking & Cautionary Statements • The Information in this document may contain “forward-looking statements”. Forward-looking statements may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “will” or words of similar meaning and in
Slide 3: Agenda
Agenda • What’s happening? • Why does this make sense? • Millipore in the short term • Millipore in the future
Slide 4: What's happening?
What’s happening? • Merck KGaA entered into a definitive agreement to acquire all outstanding Millipore shares for US$107 per share in cash, or a total transaction value (including net debt) of approximately US$7.2 bn • Represents significant shareholder value and new opportunities for Millipore emp
Slide 5: Proposal: Merck KGaA & Millipore
Proposal: Merck KGaA & Millipore
Slide 6: Why does this make sense for Merck?
Why does this make sense for Merck? • Contributes complementary high-margin specialty products with an attractive growth profile • Creates a € 2bn (~US$ 2.75 bn) world class partner for the Life Science sector • Provides significant scale in high-growth bioscience and bioproduction segments • Compre
Slide 7: Why does this make sense for Millipore?
Why does this make sense for Millipore? • Combines the strong R&D capabilities and global presence of both companies to expand our global reach, innovation capacity, customer value creation and risk diversification • Builds upon Millipore’s strong brand and a proven track record of sustainable and p
Slide 8: Combined R&D capabilities creates powerful innovation platform
Combined R&D capabilities creates powerful innovation platform • Pro forma annual R&D budget of EUR 123m focused on products for pharma and biotech customers • Increased scale helps to improve return on investment in new technologies, and diversifies risk • Make effective use of existing biopharma c
Slide 9: How does this benefit our customers?
How does this benefit our customers? • Customers in the pharma and biopharmaceutical industries will benefit from a comprehensive product offering, cutting-edge technologies and enhanced distribution platforms. • Two world class teams will join forces to open up new growth opportunities across the w
Slide 10: Millipore in the short term
Millipore in the short term • Business as Usual • Please continue to provide customers with the same high quality of products, services and expertise • No immediate impact on employees, including pay, benefits and organizational structure • We’ll keep you informed throughout the process
Slide 11: Millipore Future
Millipore Future • You are the Millipore brand and one of the most valuable assets we have! • Among some of the most talented employees in the industry • Exciting opportunities for employees • Broader, more diversified suite of products and technologies for customers • Enhanced shareholder value